- Home
- GXAI vs DOMH Comparison
GXAI vs DOMH Comparison
Compare GXAI & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- DOMH
- Stock Information
- Founded
- GXAI 2021
- DOMH 1967
- Country
- GXAI United States
- DOMH United States
- Employees
- GXAI N/A
- DOMH N/A
- Industry
- GXAI
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- DOMH Health Care
- Exchange
- GXAI Nasdaq
- DOMH Nasdaq
- Market Cap
- GXAI 8.0M
- DOMH 74.9M
- IPO Year
- GXAI 2023
- DOMH N/A
- Fundamental
- Price
- GXAI $1.18
- DOMH $5.25
- Analyst Decision
- GXAI
- DOMH
- Analyst Count
- GXAI 0
- DOMH 0
- Target Price
- GXAI N/A
- DOMH N/A
- AVG Volume (30 Days)
- GXAI 744.9K
- DOMH 1.5M
- Earning Date
- GXAI 03-26-2025
- DOMH 05-08-2025
- Dividend Yield
- GXAI N/A
- DOMH 5.93%
- EPS Growth
- GXAI N/A
- DOMH N/A
- EPS
- GXAI N/A
- DOMH N/A
- Revenue
- GXAI $2,979.00
- DOMH $12,589,000.00
- Revenue This Year
- GXAI N/A
- DOMH N/A
- Revenue Next Year
- GXAI N/A
- DOMH N/A
- P/E Ratio
- GXAI N/A
- DOMH N/A
- Revenue Growth
- GXAI N/A
- DOMH 1117.50
- 52 Week Low
- GXAI $1.01
- DOMH $0.83
- 52 Week High
- GXAI $9.74
- DOMH $13.58
- Technical
- Relative Strength Index (RSI)
- GXAI 40.91
- DOMH 44.59
- Support Level
- GXAI $1.04
- DOMH $5.18
- Resistance Level
- GXAI $1.24
- DOMH $8.55
- Average True Range (ATR)
- GXAI 0.13
- DOMH 1.30
- MACD
- GXAI 0.02
- DOMH -0.56
- Stochastic Oscillator
- GXAI 35.18
- DOMH 1.45
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.